

CIRCULARIZATION OF SINGLE-STRANDED DNA TEMPLATE IMPROVES TALEN-MEDIATED GENE INSERTION IN LONG-TERM HSC

Gil Letort¹, Aymeric Duclert¹, Diane Le Clerre¹, Isabelle Chion-Sotinel¹, Cosimo Ducani², Roger Salvatori², Margaux Sevin¹, Roman Galetto¹, Philippe Duchateau¹, and Julien Valton¹

¹Collectis S.A., 8 Rue de la Croix Jarry, 75013 Paris, France; ²Moligo Technologies, Banvaktsvägen 20, 171 48, Solna, Sweden

1-Background

- Engineered nucleases enable to generate sequence-specific double-strand breaks (DSBs) at targeted genomic loci. This facilitates the inactivation (knockout, KO) of genes or the insertion (knock-in, KI) of therapeutic genes in the presence of a DNA donor template and enables development of cell and gene therapy products for a wide array of indications. While viral vectors, particularly Adeno-Associated Viruses (AAVs), are prevalent carriers of donor templates, recent reports have raised safety and efficacy concerns over AAV related to potential genotoxicity. Thus, exploring and identifying new alternatives to vectorize DNA donor templates for engineered nucleases-mediated gene insertion purposes is highly regarded.
- Non-viral DNA donor templates such as linear single-stranded DNA (LssDNA) and circular single-stranded DNA (cssDNA) are emerging as promising options to edit Hematopoietic Stem and Progenitor Cells (HSPCs) for therapeutic applications. Capitalizing on TALEN technology, we have devised a gene editing process that incorporates non-viral DNA donor template delivery (LssDNA or CssDNA) to enhance gene insertion in HSPCs.

2-TALEN-mediated Knock-in process using LssDNA and cssDNA




Figure 1. Circularization of ssDNA increases the overall efficiency of TALEN-mediated Knock-in in HSPCs.

3-Comparison of AAV- and cssDNA-mediated Knock-in processes




Figure 2. CsdDNA/TALEN-mediated knock-in process leads to a higher engraftment of edited HSPCs than does the AAV/TALEN reference process. **A**, Representative schema of HSPCs editing protocol using a mRNA encoded TALEN targeting the *B2M* locus and cssDNA or AAV (MOI=350 vg/cell) as DNA donor templates to insert a reported gene (2.2 kb) via disruptive insertion. mRNAs encoding a viability enhancer and a HDR enhancer (Via-Enh01 and HDR-Enh01, respectively) were also incorporated in the process. The timing is indicated in days (D0-D7). Edited HSPCs retrieved 7 days post thawing were characterized by flow cytometry to assess the level of knock-in (KI) of DNA donor templates and knock-out (KO) of *B2M* as well as their viability. Their differentiation capacity into erythroid and myeloid progenitors as well as their transcriptomics profile were also assessed by colony forming unit (CFU) assay and CITE-seq, respectively. Edited HSPCs retrieved 4 days post thawing, were also injected in NCG mice to assess their ability to engraft, differentiate and keep their editing events, 16 weeks after injection onset. **B**, In vitro experimental results illustrating the frequency of cells harboring KI events, the ratio K/IKO, the viability and plating efficiency of HSPCs either untreated, electroporated (Mock EP), edited with TALEN only (TALEN), or edited with TALEN and cssDNA or AAV donor templates (cssDNA or AAV respectively). **C**, In vivo experimental results illustrating the level of human CD45+ cells (hCD45) engraftment and of KI and KO frequencies determined either before mice injection (input), or in hCD45+ cells engrafted in the bone marrow (BM) of NCG mice, 16 weeks after cells injection onset (output). Two-way ANOVA followed by Bonferroni multi-comparison test. P-values are indicated. The product of the frequency of hCD45+ cells engraftment and frequency of KI is also shown to illustrate the overall efficiency of each protocol of HSPC editing. Mann-Whitney two-tailed non-parametric unpaired test with a confidence interval of 95%. P-value is indicated. On each box plot, the central mark indicates the median, the bottom and top edges of the box indicate the interquartile range (IQR), and the whiskers represent the maximum and minimum data point. Each dot represents data obtained from one HSPCs donor.

4-Comparative CITE-Seq transcriptomics analysis of HSPCs edited by the TALEN/AAV or TALEN/cssDNA Knock-in processes




Figure 3. CsdDNA/TALEN-mediated knock-in process leads to a higher frequency of gene edited HSC-enriched subpopulation than does the AAV/TALEN reference process. **A**, **left panel**, UMAP (Uniform Manifold Approximation and Projection) plots showing aggregated 5'scRNA CITE-Seq data obtained from HSPCs either untreated, edited with TALEN and AAV or cssDNA donor templates (AAV or cssDNA respectively), 4 days post thawing and at the time of NCG mice injection onset (n=3 independent biological donors). The different cell subpopulations identified are illustrated by a color code indicated at the bottom of the graph. The HSC-enriched cell subpopulation is indicated as "HSC" for the sake of simplicity. **A, middle and right panels** illustrate the frequency of HSC-enriched subpopulations within all subpopulations and the frequency of KI within the HSC-enriched subpopulations, respectively. Each dot represents data obtained from one HSPCs donor. **B, left panel**, UMAP plots showing the cell cycle phase (G1, G2M and S) of each cells identified in UMAP. **B, right panel**, plot showing the frequency of cells in G1, G2M and S in each experimental groups (n=3 donors aggregated). **C**, Gene Set Enrichment Analysis (GSEA) obtained using the REACTOME gene set to compare the AAV and CsdDNA experimental groups to the untreated reference group and to directly compare the cssDNA group to the AAV reference group. Normalized Enrichment Score (NES) as well as Log P value obtained for each donor (n=3 independent HSPC donor) are illustrated by a red/white/blue color code and size of the dots, respectively (see legend on the right side of the figure). The different pathways found to be significantly up (red) or down (blue) regulated in the different experimental group comparisons, were numbered and aggregated in subgroups shown in the left side of the figure for the sake of clarity. The names of each numbered pathway are illustrated above.

Conclusions

- LssDNA or cssDNA can be used as DNA donor template to promote targeted gene insertion at the *B2M* locus in HSPCs using the TALEN technology.
- cssDNA yields a 3- to 5-fold higher gene insertion frequency than LssDNA, with up to 49% of HSPCs harboring a precise targeted gene insertion event.
- HSPCs edited with the cssDNA/TALEN process efficiently engraft in the bone marrow of NCG mice and retain 50% of the gene insertion events detected before injection onset. This process generates HSPCs harboring higher in vivo engraftment capacity and editing stability than those edited with the AAV/TALEN reference editing process, even when AAV is transduced at low MOI.
- The cssDNA/TALEN editing process promotes higher levels of correctly edited HSC-enriched subpopulation than the AAV/TALEN reference editing process.